Peter J. Rossi, MD

Dr. Peter Rossi

Peter J. Rossi, MD, who started practicing at Emory in 2006, is Assistant Professor of Radiation Oncology at Winship Cancer Institute of Emory University.


Radiation Oncology (Board certified since 2007)

Areas of Expertise

  • American Brachytherapy Society Fellowships in low dose rate (LDR) and high dose rate (HDR) brachytherapy for prostate cancer treatment
  • Prostate Cancer
  • IMRT/IGRT/Rapid ARC and CalypsoMedical technologies to treat prostate cancer and other cancers
  • Bladder cancer/tumors
  • Cervical/Uterine/Vulvar/Vaginal cancer
  • Testicular cancer
  • Clinical trials
  • Resident and medical student education and research

Groundbreaking Research and Clinical Trials

Dr. Rossi is an expert in prostate cancer and gynecological malignancies.  He is involved in groundbreaking studies to improve patients’ survival from prostate cancer after failure from surgery; improving outcome in patients with aggressive prostate cancer requiring upfront radiation and the need for hormonal therapy; improving patients understanding of cancer treatments by investigating ways to improve comprehension of education material and improving quality of life after treatment of prostate brachytherapy and pelvic radiotherapy. 

Through clinical studies, Dr. Rossi is identifying the appropriate amount of radiation or brachytherapy seed treatment necessary to cure prostate cancer. He is one of only a few radiation oncologists in Georgia solely dedicated to improving treatments and side effects associated with treatments for prostate cancer.

Dr. Rossi was first in Georgia to utilize Calypso medical technology—a system to localize and track prostate motion during external radiation treatments for prostate cancer to better “find” the cancer and minimize the side effect from radiation exposure to adjacent critical organs.

He was also first to treat prostate cancer using Rapid Arc technology, combined with Calypso medical technologies, one of a very few places in the world both groundbreaking treatment technologies are utilized together. Emory introduced IMRT technology in the late 1990’s to Georgia. Rapid Arc is a further improvement of the concept of this technology that Emory is one of the first to introduce to patient care of cancer.

As an academic physician involved in clinical trials to advance practice standards, Dr. Rossi teaches fellows, residents and medical students, and directs patient care. He works in the only NCI-designated cancer center in Georgia, integrating surgical oncology, medical oncology, radiation oncology, pathology, radiology and a multitude of ancillary services to best assist patients with newly diagnosed or recurrent cancer.

He is principal investigator for institutional and national clinical research studies to advance current care of patients with cancer.

Dr. Rossi writes questions for national board exams for radiation oncologists. He has multiple publications in international peer reviewed journals focusing on improving treatment outcomes in prostate cancer and gynecological malignancies.  He serves on editorial review boards and scientific education committees for notable radiation oncology journals and national/international radiation oncology organization.  He is the vice-chair of a committee in the national organization of radiation oncologists (ASTRO).

He has written studies for novel interventions to improve the quality of life of patients receiving brachytherapy for prostate cancer or external radiation therapy for treatment of prostate cancer or gynecological malignancies. He lectures and instructs nationally on the technique/skill of brachytherapy or seed implants for the treatment of prostate cancer. He is involved in establishing practice quality review (PQR) standards for other radiation oncologist to measure their skill/quality of cancer care.

The Road to Emory: Education

  • Medical School: Wayne State University School of Medicine, Detroit, MI, 1997
  • Internship: Naval Medical Center, San Diego, CA, 1998
  • Residency: Wake Forest University Medical Center, Winston-Salem, NC, 2006


  • American Brachytherapy Society
  • American Medical Association
  • American Radium Society
  • American Society for Therapeutic Radiology and Oncology


  • ABS Prostate Brachytherapy Fellowship Award
  • ABS LDR and HDR Brachytherapy Fellowship Award

Major or Recent Publications

  • Boost first, eliminate systematic error, and individualize CTV to PTV margin when treating lymph nodes in high-risk prostate cancer. Rossi PJ, Schreibmann E, Jani AB, Master VA, Johnstone PA. Radiother Oncol. 2008 Oct 24.
  • PMID: 18952307
  • Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone. Rossi PJ, Urbanic J, Clark PE, McCullough DL, Lee WR. Brachytherapy. 2008 Oct-Dec; 7(4):286-9.
  • PMID: 18928924
  • Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: a SEER registry analysis. Rossi PJ, Jani AB, Horowitz IR, Johnstone PA. Int J Radiat Oncol Biol Phys. 2008 Jan 1; 70(1):134-8. Epub 2007 Sep 12.
  • PMID: 17855014
  • Applying population dynamics modeling to patients with lymph node positive prostate cancer. Johnstone PA, Riffenburgh RH, Rossi PJ, Assikis V, Master VA, Jani AB. J Urol. 2007 Nov; 178(5):1952-5; discussion 1955-6. Epub 2007 Sep 17.
  • PMID: 17868720
  • Grade migration in prostate cancer: an analysis using the Surveillance, Epidemiology, and End Results registry. Jani AB, Master VA, Rossi PJ, Liauw SL, Johnstone PA. Prostate Cancer Prostatic Dis. 2007; 10(4):347-51. Epub 2007 May 15.
  • PMID: 17505529
  • A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. Papagikos MA, Rossi PJ, Urbanic JJ, deGuzman AF, McCullough DL, Clark PE, Lee WR. Am J Clin Oncol. 2007 Apr; 30(2):199-204.
  • ‘Insignificant' prostate cancer on biopsy: pathologic results from subsequent radical prostatectomy. Johnstone PA, Rossi PJ, Jani AB, Master V. Prostate Cancer Prostatic Dis. 2007; 10(3):237-41. Epub 2007 Mar 27. Review.
  • PMID: 17387320
  • Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancer. Rossi PJ, Clark PE, Papagikos MA, McCullough DL, Lee WR. Urology. 2006 Feb; 67(2):349-53.
  • PMID: 16461084
  • MRSI after treatment for prostate cancer: Is it worth it? ASTRO presentation, November, 2006.


First and foremost a family man, Dr. Rossi is married to Mila Rossi, who has a Master’s degree in Public Administration and works for the CDC Foundation. They have a daughter, Giada. He enjoys family hiking outings in the North Georgia and North Carolina mountains and alpine skiing. His hobbies are long-distance running and biking and he competes in triathlons. He enjoys visiting North Michigan in the summer and reconnecting with his five brothers and sisters and their families. He chose academic medicine to be at the forefront of medicine to provide the very best oncologic care available and to be able to train future cancer physicians.